News

Change is in the air as a new year begins. These five trends will continue to gain momentum in the healthcare industry.

There's good news in efforts to combat HIV/AIDs and hepatitis C (hep C, HCV). Some feel, however, that policymakers could do more to prioritize resources to fully eradicate the diseases.

The changing healthcare industry is leading organizations to prioritize new skill sets during recruitment efforts.

Tips to help healthcare executives present their most authentic selves during remote interviews.

The solution to succeeding in value-based reimbursement models is to start inside the hospital with high acuity patients and build the systems that support them.

Optimism exists for biosimilars in the United States, but questions regarding FDA approval and reimbursement remain.

Some providers and payers are hesitant to jump on board with telemedicine, but others say it the benefits are clear.

In late December, FDA approved AstraZeneca’s Zurampic (lesinurad) 200-mg tablets in combination with a xanthine oxidase inhibitor (XOI) for high levels of uric acid in the blood (hyperuricemia) associated with gout.

FDA approved expanded age indication for Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil 9, Merck) in males.

Survey reveals how size impacts health plan challenges, priorities, outlook, and technology use.

Survey reveals how size impacts hospitals' challenges, priorities, outlook, and technology use.

Here's how more than 600 healthcare executives responded to questions related to reimbursement, pharmaceuticals, consumerism, consolidation, technology, and more.

From changing leadership to new payment models, find out what to expect and how to succeed in 2016.

The FDA recently granted orphan drug approval to Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

In the latest controversy over drug pricing, an organization said that the price of GlaxoSmithKline’s Nucala (mepolizumab), an injectable indicated for severe asthma patients with eosinophilic inflammation, is far over-priced.

Sales of Merck’s Keytruda (pembrolizumab) are expected to increase, after FDA approved the drug for first-line treatment of melanoma.

The Association for Community Affiliated Plans recently convened 13 plans to take on together the issue of prescription drug abuse.

FDA approved insulin glargine injection (Basaglar, Eli Lilly) to improve glycemic control in patients with diabetes mellitus.

In this opinion piece, members of the Council for Affordable Health Coverage call for support for the Small Business Healthcare Relief Act.

The role of insurance chief operating officer role has expanded greatly in recent years, with responsibilities becoming more strategic and aligned with those of the CEO.

Better management on several fronts should be able to reduce a hospital’s readmissions, but it requires commitment and attention to detail.

Humana’s Medicare Advantage members show better quality, healthier outcomes and lower costs through value-based models.

Four new drugs and a biosimilar should be on your radar.

Pete Mulliner, an IPF patient and ambassador for the Pulmonary Fibrosis Foundation, discusses how he believes physicians should treat patients who have been recently diagnosed with IPF.

As the healthcare system’s historical transformation continues in 2016, managed care organizations should brace for change.

When it comes to managing rheumatoid arthritis drugs, cost comes in various sizes and shapes.

What Managed Healthcare Executive content was most popular this year? Find out here.

We asked the Managed Healthcare Executive editorial advisory board to identify the top healthcare challenge in 2015. Here's what they said.

FDA approved Bridion (sugammadex) injection today – after a long wait by Merck & Co. – to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, used during certain types of surgery.

Valeant Pharmaceuticals just entered into a new fulfillment agreement with Walgreens and says it will reduce prices of its branded prescription-based dermatological and ophthalmological products such as Jublia by 10 percent.